

20 December 2018

The Manager
Companies Announcement Office
Australian Securities Exchange
Electronic Lodgment

Dear Sir/Madam,

ASX RELEASE – CHANGES TO ASIAN AMERICAN RADIATION & ONCOLOGY (“AARO”) SHAREHOLDING

The Board of Directors (“**the Board**”) of Asian American Medical Group Limited (“**AAMG**” or “**the Company**” and together with its subsidiaries, “**the Group**”) wishes to announce a change in the shareholding of its subsidiary Asian American Radiation & Oncology (“**AARO**”) in relation to the Group’s Incentive Option Scheme, which permits directors and employees to own shares in the Company and its subsidiaries.

Dr Jonathan Teh Yi Hui (“**Dr Teh**”), a Consultant Radiation Oncologist employed by AARO, has exercised his rights to the Incentive Option Scheme with the purchase of 10,000 ordinary shares in AARO at S\$5.50 each, amounting to an aggregate consideration of S\$55,000. Following the exercise, Dr Teh holds approximately 2.0% of all issued shares in AARO.

As a result of the above, AAMG’s shareholding in AARO is reduced from 70% to 69%.

The Board encourages directors and senior executives to own shares in the Group to align their interests more closely with those of shareholders. The change is not expected to have a material impact on AAMG’s net tangible assets per share or earnings per share for the current financial year.

On behalf of the Board,

DARIO NAZZARI
Company Secretary

About Asian American Medical Group

Asian American Medical Group (“**AAMG**”) is based in Singapore and has been listed on the Australian Securities Exchange since September 2009. The Group’s operations include the Asian American Liver Centre Pte Ltd (“**AALC**”), established in 1994 in Singapore, and Asian American Radiation Oncology Pte Ltd (“**AARO**”).

The Group entered into a strategic collaboration in October 2012 with the US-based US\$19-billion integrated global health enterprise University of Pittsburgh Medical Center. UPMC, ranked No. 14 on the U.S. News & World Report Honor Roll of American’s Best Hospitals, is

affiliated with the University of Pittsburgh Schools of the Health Sciences and are pioneers in the field of transplantation. This collaboration has enhanced AAMG's clinical capabilities through shared protocols, rigorous quality standards and technology and also created a platform for AAMG to expand into other countries in Asia such as Malaysia and Myanmar.

AALC, one of Asia's foremost liver centres, is led by renowned hepatobiliary expert and liver transplant surgeon, Dato' Dr. Tan Kai Chah (Dr. KC Tan), who helped start the Liver Transplant Programme at the King's College Hospital London, United Kingdom, and pioneered the highly successful Living Donor Liver Transplantation (LDLT) Programme in Singapore. In 2014, AALC began conducting surgical procedures at the IHEAL Medical Centre located in Kuala Lumpur, Malaysia.

AARO, established in March 2015, offers radiation oncology clinical, consultancy and management services and is led by Dr Daniel Tan Yat Harn. Based in Singapore, AARO will drive expansion into the growing radiotherapy and oncology segment in the overseas market, at a time where there is a shortage of modern radiotherapy treatment centres.

For further information, please visit: www.aamg.co

Media contact:

WeR1 Consultants Pte Ltd
3 Phillip Street, #12-01
Royal Group Building
Singapore 048693
aamg@wer1.net
Tel: +65 6737 4844